世界中医药

目的:探讨益气除痰方联合静脉化疗治疗晚期非小细胞肺癌(NSCLC)的疗效及免疫学机制。方法:选取2014年6月至2017年12月复旦大学附属中山医院青浦分院收治的晚期NSCLC患者80例作为研究对象,按照随机数字表法分为观察组和对照组,每组40例。观察组接受益气除痰方联合静脉化疗,对照组仅接受静脉化疗。评估化疗整体效果,测定血清肿瘤标志物、免疫细胞因子含量及外周血免疫细胞含量。结果:化疗4个周期后,观察组患者的客观有效率(OR)以及血清干扰素-γ(IFN-γ)含量、外周血辅助性T细胞1(Th1)含量明显高于对照组,血清癌胚抗原(CEA)、细胞角蛋白片段21-1(CYFRA21-1)、鳞状细胞癌抗原(SCC-Ag)、白细胞介素-4(IL-4)、白细胞介素-10(IL-10)、白细胞介素-17(IL-17)含量以及外周血辅助性T细胞2(Th2)、辅助性T细胞17(Th17)、调节性T细胞(Treg)含量明显低于对照组。结论:益气除痰方联合静脉化疗治疗晚期NSCLC能够改进疗效、提高抗肿瘤免疫应答。

English Summary:

To study the efficacy and immunological mechanism of Yiqi Chutan Recipe combined with intravenous chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:A total of 80 patients with advanced NSCLC diagnosed in Zhongshan Hospital Affiliated to Fudan University Qingpu Branch from June 2014 to December 2017 were randomly divided into an observation group receiving Yiqi Chutan Recipe combined with intravenous chemotherapy，and a control group receiving intravenous chemotherapy，with 40 cases in each group.Then overall effect of chemotherapy was evaluated，and serum tumor markers，immunocytokines and peripheral blood immunocytes were measured.Results:After 4 cycles of chemotherapy，the objective response rate(OR)，serum interferon-γ(IFN-γ)，peripheral blood T helper cell 1(Th1)in the patients of the observation group were significantly higher than those in the control group; serum carcinoembryonic antigen(CEA)，cytokeratin fragment 21-1(CYFRA21-1)，squamous cell carcinoma antigen(SCC-Ag)，interleukin-4(IL-4)，interleukin-10(IL-10)，interleukin-17(IL-17)and peripheral blood T helper cell 2(Th2)，T helper cell 17(Th17)，regulatory T cell(Treg)were significantly lower than those in the control group.Conclusion:Yiqi Chutan Recipe combined with intravenous chemotherapy in the treatment of advanced NSCLC can improve the efficacy and enhance the anti-tumor immune response.

查看全文查看/发表评论下载PDF阅读器